Tétu, P.; Delyon, J.; André, J.; Reger de Moura, C.; Sabbah, M.; Ghanem, G.E.; Battistella, M.; Mourah, S.; Lebbé, C.; Dumaz, N.
FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma. Cancers 2020, 12, 1062.
https://doi.org/10.3390/cancers12051062
AMA Style
Tétu P, Delyon J, André J, Reger de Moura C, Sabbah M, Ghanem GE, Battistella M, Mourah S, Lebbé C, Dumaz N.
FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma. Cancers. 2020; 12(5):1062.
https://doi.org/10.3390/cancers12051062
Chicago/Turabian Style
Tétu, Pauline, Julie Delyon, Jocelyne André, Coralie Reger de Moura, Malak Sabbah, Ghanem E Ghanem, Maxime Battistella, Samia Mourah, Céleste Lebbé, and Nicolas Dumaz.
2020. "FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma" Cancers 12, no. 5: 1062.
https://doi.org/10.3390/cancers12051062
APA Style
Tétu, P., Delyon, J., André, J., Reger de Moura, C., Sabbah, M., Ghanem, G. E., Battistella, M., Mourah, S., Lebbé, C., & Dumaz, N.
(2020). FGF2 Induces Resistance to Nilotinib through MAPK Pathway Activation in KIT Mutated Melanoma. Cancers, 12(5), 1062.
https://doi.org/10.3390/cancers12051062